Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.53 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402574 | 1.00 | ANPEP (0.53) | ANPEPENPEPGABRPGABRDGABRA1 | |
| SCHEMBL18897847 | 1.00 | ANPEP (0.53) | ANPEPENPEPGABRPGABRDGABRA1 | |
| SCHEMBL22824208 | 0.88 | ENPEP (0.46) | ANPEPENPEPTSHRNFKB1 | |
| SCHEMBL12655762 | 0.83 | ALDH1A1 (0.38) | ANPEPENPEP | |
| SCHEMBL16387146 | 0.82 | FOLH1 (0.42) | ANPEPENPEPGABRPGABRDGABRA1 | |
| SCHEMBL19705849 | 0.82 | FOLH1 (0.42) | ANPEPENPEPGABRPGABRDGABRA1 | |
| SCHEMBL21151131 | 0.82 | FOLH1 (0.42) | ANPEPENPEPGABRPGABRDGABRA1 | |
| SCHEMBL24491335 | 0.81 | LMNA (0.40) | ANPEPENPEP | |
| SCHEMBL20636303 | 0.81 | KMT2A (0.39) | ANPEPENPEPCYP1A2BLMMEN1 | |
| SCHEMBL17301601 | 0.81 | SLC6A2 (0.50) | ANPEPENPEPGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451209-A4 | TETRA-,PENTA-,HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2009-06-03 | — | — | EP | claimed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| EP-1451209-A2 | TETRA-,PENTA-,HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1451210-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-09-01 | — | — | EP | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-20030125261-A1 | Penta- and hexapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-07-03 | — | — | US | claimed |
| US-20030109455-A1 | HEPTA-, OCTA-and nonapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | claimed |
| US-20030105022-A1 | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-06-05 | — | — | US | claimed |
| US-20030105023-A1 | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-05 | — | — | US | claimed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | claimed |
| WO-2003037268-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| WO-2003037266-A2 | TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-3912641-A1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | Seagen Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-5004811-A | Photodiagnosis, phototherapy of tumors and cancerous tissues | NIPPON PETROCHEMICALS COMPANY, LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| EP-0322795-A2 | Novel tetrapyrrole aminocarboxylic acids | Nippon Petrochemicals Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | VIP, SI, PDCD5 | ANPEP 2034/4885ENPEP 1289/4885GABRP 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.